Anacor Completes Patient Enrollment for AN2690 Drug Trial

Anacor has completed enrollment of approximately 600 patients in the first of two Phase 3 trials for Tavaborole for the treatment of onychomycosis.

California-based biopharmaceutical company Anacor Pharmaceuticals has completed patient recruitment in the first of two Phase 3 trials of a topical anti-fungal product Tavaborole (AN2690), used to treat onychomycosis.

The Phase 3 trial includes two double-blind vehicle-controlled trials with two-to-one randomisation between tavaborole and vehicle (the topical formulation without the active ingredient).

As per Special Protocol Assessment with the FDA, the primary efficacy endpoint is a complete cure of the great toenail at week 52.

Anacor Pharmaceuticals CEO David Perry said,"We have completed enrollment of approximately 600 patients in the first of t